4 results
The BioNIR is non-inferior to the Resolute for the primary angiographic of in-stent late loss at 6 months
1) The BioNIR is non-inferior to the Resolute for the primary clinical endpoint of target lesion failure (TLF) (defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR) at 12 months2/ The BioNIR is non-inferior to…
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
The primary objectives are to assess the safety and feasibility ofthe baroloop device for the treatment of subjects with hypertension (HTN). The secondary objective is to document the effect of the baroloop device on the blood pressure and quality…